Moderna stock: TD Cowen raises target for Moderna stock to USD 90.00

Published on 10/23/2026 at 16:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna's results are due on November 6, 2026. Moderna stock costs EUR 179.73 on October 23, 2026, 0.99 percent below the Tradegate close.

Analyst target and reporting date

TD Cowen changed its target from USD 40.00 on October 21, 2026.
Moderna reported USD 145.00 million in second-quarter revenue on July 31, 2026.
Moderna stock costs EUR 179.73 at Lang & Schwarz on October 23, 2026 at 4:07 p.m. CEST, 0.99 percent below the Tradegate close of October 22, 2026.
Moderna will report third-quarter 2026 results on November 6, 2026.

Moderna Inc., US60770K1079, Illustration mit AI erstellt.

Moderna Inc. (ISIN US60770K1079) faces a sharply lower analyst target after TD Cowen raised its price target from USD 40.00 to USD 90.00 while keeping a Hold rating on October 21, 2026, according to Investing.com. The USD 90.00 target sits 54.20 percent below the Nasdaq quote of USD 196.51 on October 23, 2026 at 10:18 a.m. ET. Moderna stock was trading at EUR 179.73 at Lang & Schwarz on October 23, 2026 at 4:07 p.m. CEST, down 0.99 percent versus the Tradegate close of EUR 181.52 on October 22, 2026.

Revenue reached USD 145.00 million

Moderna reported second-quarter 2026 revenue of USD 145.00 million and a GAAP net loss of USD 782.00 million, equal to diluted GAAP earnings per share of minus USD 1.97. Revenue exceeded the USD 102.93 million consensus estimate, while the loss per share was better than the USD 2.03 consensus loss, according to MarketBeat. The results were released on July 31, 2026, and revenue was 2.10 percent higher than in the year-earlier quarter.

Stock stays below its yearly high

Moderna's primary listing is on Nasdaq under ticker MRNA. The USD 196.51 quote on October 23, 2026 stood within the USD 22.28 to USD 254.48 52-week range, leaving the stock 22.78 percent below its high. Market capitalization was USD 78.5 billion at the same market-data timestamp. Moderna's intraday volume was 8,566,799 shares.

When are the next dates?

Moderna will report third-quarter 2026 financial results on November 6, 2026, at 8:00 a.m. ET, according to the company release carried by Newswire. The same release schedules an investor event for October 24, 2026, at 7:00 p.m. CEST. The upcoming dates leave TD Cowen's target as the clearest quantified valuation counterpoint to the current share price.

Comparison with peers

Moderna: down 0.99 percent, negative P/E 24.74, market capitalization USD 78.5 billion. Pfizer (NYSE, USD): down 1.71 percent, P/E 39.53, market capitalization USD 170.4 billion. BioNTech (Nasdaq, USD): down 2.31 percent, negative P/E 11.77, market capitalization USD 22.0 billion.

Price and valuation remain divided

Moderna combines a USD 196.51 Nasdaq quote with a USD 90.00 TD Cowen target and a USD 101.45 average target from 25 brokerages, according to MarketBeat. The contrast puts the November 6 results and Moderna's oncology pipeline in focus for valuation-sensitive investors. Moderna was trading at EUR 179.73 at Lang & Schwarz on October 23, 2026 at 4:07 p.m. CEST, 0.99 percent below the Tradegate close of October 22, 2026 at EUR 181.52. The further course of trading is shown by the continuously updated real-time quote of Moderna stock.